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Abstract
Immune niche with its huge cell diversity including more specifically tumour infiltrat-
ing lymphocytes (TILs), tumour-associated macrophages (TAMs) regulate osteosarcoma 
(OS) microenvironment. TAMs exert differential activities in the tumour development 
according to their polarisation. Indeed, in oncology, M1-polarised macrophages are 
considered as anti-tumour effectors, and M2-polarised macrophages are defined as pro-
tumour modulators by increasing the neoangiogenic process. TAM density is correlated 
with tumour cell proliferation, invasion, metastasis and poor prognosis in various epi-
thelial and haematological cancers and in bone metastasis. Similarly, tumour infiltrating 
lymphocytes play a key role in tumour development by inducing a local tolerant envi-
ronment favourable for the tumour growth. The present chapter will describe the main 
roles of the immune system in the pathogenesis of osteosarcoma and the most recent 
therapeutic development based on its regulation.
Keywords: osteoimmunology, osteosarcoma, macrophage, lymphocyte, 
microenvironment
1. Introduction
In recent years, there has been a dramatic increase in the importance given to the theory 
that the tissue microenvironment participates in determining the “bone niche” in the pro-
gression of bone tumours and in establishing resistance processes to conventional therapies. 
Originally, the concept of tumour niche has emerged based on the “seed and soil theory” 
proposed by Stephan Paget at the end of the nineteenth century [1, 2]. This tumour niche is 
defined as a specific microenvironment promoting the emergence of cancer initiating cells 
and providing all the factors required for their quiescence, proliferation and migration. 
© 2017 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
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Therefore, the tumour microenvironment is composed of a complex, interconnected network 
of protagonists, including soluble factors such as cytokines, extracellular matrix compo-
nents, interacting with fibroblasts, endothelial cells, immune cells and various specific 
cell types depending on the location of the cancer cells (e.g. osteoblasts, osteoclasts in the 
bone tissue or pulmonary epithelium in case of lung metastasis). This cellular diversity 
defines three main “niches” depending on their functional implication: an immune niche 
involved in local immune tolerance, a vascular niche associated with tumour cell extrava-
sation/migration and a metastatic niche (e.g. bone, lung and liver) hosting the metastatic 
tumour cells [3, 4].
The concept of “bone niche” was initially described in the context of haematological malig-
nancies, such as leukaemia [5] or multiple myeloma [6], and then extended to bone metasta-
ses, such as breast or prostate cancers [7]. As all tumours, the pathogenesis of osteosarcoma 
(OS) is closely related to the microenvironment in which the tumour grows. Even though the 
aetiology of OS has not been clearly established, its development has the special feature of 
being strongly associated with the “soil” described by Paget. In physiological and pathologi-
cal bone tissue, the various cells communicate together by direct contacts involving adhesion 
molecules or channels, but also in an autocrine/paracrine/endocrine manner involving cyto-
kines and growth factors [8]. Among these glycoproteins, the triad osteoprotegerin (OPG)/
Receptor Activator of NF-κB (RANK)/RANK Ligand (RANKL) plays a pivotal role in OS 
development [9]. In case of OS, there is effectively a dysregulation in this balance between 
OPG/RANK/RANKL, provoking exacerbated local bone remodelling (Figure 1). As a result, 
numerous factors initially trapped in this matrix are released, which in turn stimulate sarcoma 
cell proliferation, leading to the establishment of a vicious cycle between bone and tumour 
cells [10]. These events are associated with early and late events in the metastatic process by 
promoting the neoangiogenesis and extravasation of tumour cells [11, 12]. But until today, 
the characterisation of the microenvironment of OS has not been fully documented [13, 14]. 
The immune niche, with its huge cell diversity including more specifically tumour infiltrating 
lymphocytes (TILs) and tumour-associated macrophages (TAMs), regulates the OS micro-
environment [15, 16]. TAMs exert different effects on tumour development because of their 
polarisation. In oncology, M1-polarised macrophages are considered to be anti-tumour effec-
tors, and M2-polarised macrophages are defined as pro-tumour modulators as they increase 
the neoangiogenic process [17–19]. The density of TAMs is correlated with tumour cell pro-
liferation, invasion, metastasis and poor prognosis in various epithelial and haematological 
cancers and in bone metastases [20].
Osteoimmunology is a recent term proposed for describing the complex immune environment 
controlling the bone remodelling and related diseases [21]. Several reports have underlined 
the therapeutic interest to use immunotherapies or immunomodulatory-based therapies for 
OS. In this context, the number of new drugs activating the immune system has exploded in 
the last 10 years, and numerous phase I and II clinical trials are in progress in OS. The present 
chapter will describe the main roles of the immune system in the pathogenesis of OS and the 
most recent therapeutic development based on its regulation.
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2. The immune niche in osteosarcoma
As said above, the niche of OS is composed of a complex network of diverse cells, which 
interact together by direct contacts, or in an autocrine/paracrine/endocrine manner involving 
cytokines and growth factors. This chapter will focus specifically on the main cellular pro-
tagonists: lymphocytes, macrophages and the principal associated cytokines.
2.1. Tumour infiltrating lymphocytes (TILs)
Heterogeneity of tumour cells with various osteosarcoma sub-entities further complicates 
identification of robust biomarkers with broad clinical application [22]. Analysis of the tumour 
microenvironment in patients with a variety of haematological pathologies and solid tumours 
such as bone metastases and soft tissue sarcomas has revealed that a major subset of tumours 
shows evidence of a T cell–infiltrated phenotype [23, 24]. Selected T lymphocytes migrate from 
secondary lymphoid organs to the tumour sites and invade the tumour tissues. They are com-
posed of various T lymphocyte subpopulations, which exhibit highly specific immunological 
Figure 1. Osteosarcoma and its niches. In osteosarcoma, the microenvironment plays a pivotal role in the pathogenesis 
of tumour cells. It facilitates the transport of gas and nutriments to cancer cells and extravasation to their metastatic 
location (vascular niche), induces a tolerant environment (immune niche) and dysregulates bone remodelling (bone 
niche), in which the molecular OPG/RANKL/RANK triad plays a key role in regulation. OPG and RANKL are produced 
by osteoblasts and/or stromal cells, whereas RANK is expressed at the surface of osteoclasts and their precursors. The 
immune niche is one of the source of therapeutic targets against osteosarcoma.
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reactivity compared to circulating and non-infiltrating lymphocytes [25]. The final immune 
response resulting from the activation of T lymphocytes is complex and depends on the 
nature of these T cells (e.g. Treg, CD4+) and the presence of the other immune protagonists 
such as macrophages.
As other immune cells, lymphocytes seem to play an essential role in osteosarcoma growth 
and prognosis, but publications reporting this population in OS remain rare [16, 22, 26]. The 
presence of T lymphocytes in human OS tissues was previously studied by Trieb et al. by 
immunohistochemical techniques [26]. Phenotypic analyses have revealed that the infiltrat-
ing lymphocytes into OS were 95% CD3+ and 68% CD8+. At this time, human CD4+ Treg was 
unknown and not included in the study, which did not detect any correlation of TILs with OS 
outcome. A few years later, Theoleyre et al. supported the presence of specific T subpopula-
tions in OS: TILs isolated from OS samples exhibited lytic activity in vitro, which were appar-
ently no efficient in patients [16]. The study of the microenvironment has a strong impact 
on targeted patient treatment for which little progress has been achieved since introduction 
of neo-adjuvant chemotherapy 30 years ago. Prognostic biomarkers for risk stratification at 
the time of diagnosis are missing and are a major drawback in clinical testing of novel thera-
peutic agents. Alternatively, analysis of the tumour microenvironment for osteosarcoma out-
come-related biomarkers might be less dependent from the osteosarcoma subtype. Recently, 
Fritzsching et al. have reported for the first time CD8+/FOXP3+ ratio as strong prognostic fac-
tor at time of OS diagnosis, pointing out the functional key role of Treg in OS pathogenesis. 
Multivariate analysis showed that this novel parameter was independent from tumour metas-
tasis and response to neoadjuvant chemotherapy and could be validated in an independent 
patient cohort with current state of diagnosis and treatment of OS [22]. It has been suggested 
in other solid tumours (e.g. colon cancers) that intensity of tumour microenvironment infil-
tration with T-cells, especially cytotoxic tumour infiltrating CD8+T-cells (CD8+ TILs) allows 
more powerful prognostic staging than traditional staging. The characterisation of this simple 
immune system-based biomarker has been termed the “immunoscore”, and this is currently 
tested for some tumours in a multicenter study [27, 28].
Lymphocytes are immune cells regulated by diverse cytokines, in particular the triad OPG/
RANK/RANKL, which represents a setting up a fertile soil for cancer cells as well [9]. Bone 
remodelling results from a balance between two opposite cellular activities: (i) osteoblasts in 
charge of the synthesis of new organic extracellular matrix, which will become progressively 
mineralized and (ii) osteoclasts specialised in the degradation of the mineralised extracellular 
matrix, process named bone resorption. Osteoclastogenesis and osteoclast activities are regu-
lated by a master cytokine called NF-κB Ligand (RANKL), member of the tumour necrosis 
factor (TNF) superfamily (official TNF nomenclature: TNFSF11) [9]. RANKL is a soluble and/
or membrane cytokine expressed by osteoblasts and stromal cells, binds to RANK a membrane 
receptor expressed at the surface of mature osteoclasts and their precursors. RANKL binding to 
RANK induces specific NF-κB–dependent signal transduction pathways and stimulates osteo-
clast differentiation, survival and resorption activity. RANKL binds to a soluble receptor named 
osteoprotegerin (OPG), which is a ubiquitous protein and acts as a decoy blocking RANKL 
binding to RANK [29]. OPG is then considered as a strong inhibitor of osteoclastogenesis and 
bone resorption. LGR4 is the last receptor of RANK recently identified. LGR4 expressed at 
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the osteoclast/osteoclast precursor membrane is a negative regulator of RANKL-RANK acti-
vation (see review in Ref. [9]). It is widely accepted that the multiple components of the bone 
niche (e.g. soluble factors, extracellular matrix) strongly contribute to the bone tumour initia-
tion and the metastatic process [30, 31]. RANKL influences the microenvironment of cancer 
cells by acting on the local immunity. Indeed, the major role of RANKL in the immune system 
has been initially identified in RANKL-knockout mice in which the development of secondary 
lymphoid organs was impaired especially the lymph nodes [32] but also at the “central” level 
where the maturation of thymic epithelial cells necessary for T cell development was affected 
[33]. RANKL is also involved in the modulation of the immune response by inducing T cell 
proliferation [34] and dendritic cells survival [29]. Indeed, activated T cells through RANKL 
expression stimulate dendritic cells, expressing RANK, to enhance their survival and thereby 
increase the T cell memory response [34]. More recently, Khan et al. demonstrated that RANKL 
blockade can rescue melanoma-specific T cells from thymic deletion and increases anti-tumour 
immune response as shown in melanoma [35]. In 2007, Mori et al. reported for the first time 
functional RANK expression in human OS cells strengthening the involvement of the RANK/
RANKL/OPG axis in OS [36, 37]. Moreover, in animal OS models, OPG gene transfer prevents 
the formation of osteolytic lesions associated with OS development, in reducing the tumour 
incidence and the local tumour growth, leading to a fourfold increase in mice survival 28 days 
post-implantation [38]. This opened a new door of novel therapeutic approaches for OS.
2.2. Tumour-associated macrophages (TAMs)
The mononuclear phagocyte system is composed by heterogeneous populations participating 
in the body’s first line of defence against pathogens and parasites [39]. This system includes 
cells circulating cells into the body fluids such as monocytes, and integrates resident cells 
such as macrophages, dendritic cells (DC) and their precursors located in the bone marrow 
[40]. Their production and activities are controlled by numerous cytokines and growth factors 
but are more specifically regulated by the two ligands of macrophage-colony stimulating fac-
tor (M-CFR, cFMS or CD115): M-CSF (or CSF-1) and interleukin (IL)-34 [41, 42].
TAMs are the predominant leukocytes infiltrating solid tumours and can represent up to 50% 
of the tumour mass. These cells play a pivotal role in tumour behaviour illustrated by the 
significant link between TAM number and density and the prognosis [18, 43, 44]. Whereas 
TAMs can exert anti-tumour activities, the ambiguous role of macrophages in tumour pro-
gression is reflected in the finding that TAMs can also actively contribute to each stage of 
cancer development and progression [45]. Macrophage subtypes are conventionally classified 
in M1 considered as the classical population and M2 identified as an alternative subpopula-
tion in link to their differentiation/activation state. However, if the parallel between M1 and 
M2 can be drawn with the Th1 and Th2 T lymphocyte classification, Th1/Th2 cells do not 
regulate macrophage polarisation. On the contrary, macrophage subtypes are versatile, are 
non-permanent cell populations, initiate and influence T lymphocyte polarisation resulting 
in differential immune response (e.g. Th1 response against virus and bacteria, Th2 response 
against parasites) [46]. Indeed, M1 and M2 macrophages are characterised by specific profiles 
of cytokine secretion. M1 macrophages are characterised by the secretion of IL-12, IL-1, IL-6, 
TNF or ROS, considered as pro-inflammatory mediators and directly involved in the control 
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of infections and anti-tumour activities. On the opposite, M2 macrophages constitute a het-
erogeneous population (M2a, b and c) inducing a Th2 immune response and secreting IL-4, 
IL-10 and IL-13. M2 macrophages are pro-angiogenic, pro-fibrotic and pro-tumorigenic.
The exact role of macrophages in OS is still unclear and controversial. Some studies have 
defined TAMs as anti-tumour effectors. Buddingh et al. thus demonstrated that higher TAM 
infiltration was associated with better overall survival in high-grade osteosarcoma. However, 
the authors did not observe any differences between metastatic and non-metastatic osteosar-
comas, and TAMs exhibited both M1 and M2 characteristics [47]. On the contrary, the impact 
of macrophages in tumour development has been also suspected. Lewis and Pollard distin-
guished the anti-tumour M1-macrophages from M2-macrophages leading to tumour growth 
and invasion, angiogenesis, metastasis and immune-suppression [18]. OS development may 
thus be accompanied by a switch in the phenotype of infiltrating TAMs, from anti-metastatic 
M1-macrophages to pro-metastatic M2-macrophages. This hypothesis is in agreement with 
the in vivo work described by Xiao et al. who showed a switch in macrophage subpopu-
lations in a mouse model of human osteosarcoma from M1-macrophages during the first 
week of tumour growth, to M2-macrophages after 2–3 weeks [48]. In addition, Pahl et al. 
demonstrated that human M1-like macrophages can be induced to exert direct anti-tumour 
activity against osteosarcoma cells, mediated by TNF-α and IL-1β [49]. In the same manner, 
Ségaliny et al. demonstrated that osteosarcoma cells expressed IL-34, increasing the recruit-
ment of M2-polarised macrophages into the tumour tissue, which correlates with tumour 
vascularization and the metastatic process [50]. TAMs accumulate in tumour microenviron-
ment and according to their M2 or M1 phenotype contribute to tumour growth, angiogenesis 
and metastasis [51]. RANK is present at the cell membrane of monocytes/macrophages and 
RANKL acts as chemoattractant factor for these cells [52]. M2 subtype is strongly associated 
with the angiogenic process and interestingly RANK is mainly expressed by M2 macrophage 
subtype [53]. RANK/RANKL signalling in M2 subtype modulates the production of chemo-
kines promoting the proliferation of Treg lymphocytes in favour of an immunosuppressive 
environment [54]. In breast carcinoma, RANKL is mainly produced by CD4+CD25+ T lym-
phocytes expressing Foxp3 and corresponding to Treg lymphocytes. In this context, a vicious 
cycle is established between TAMs, Treg and tumour cells resulting in the tumour growth, the 
spreading of cancer cells and the amplification of the metastatic process [55].
2.3. Recent therapeutic developments based on the regulation of the immune system of 
osteosarcoma: immunomodulating drugs
The therapeutic protocol currently used for osteosarcoma was established by Rosen et al. at 
the end of the 1970s [56]. It comprises preoperative (neoadjuvant) chemotherapy associating 
mainly four drugs (doxorubicin, cisplatin, methotrexate and ifosfamide) [57], and followed by 
surgical removal of all detectable disease (including metastases), and postoperative (adjuvant) 
chemotherapy, preferably within the setting of clinical trials [58]. OS is considered resistant to 
applicable doses of radiation [59, 60]. Supplemental therapeutic approaches such as chemoem-
bolisation or angioembolisation, thermal ablation, radiofrequency ablation and cryotherapy 
are experimental or palliative [59]. Unfortunately, patients, who are diagnosed with meta-
static disease or who relapse post-therapy have an extremely poor prognosis, with little to no 
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improvements in survival seen over the past 30 years [61]. Several reports have underlined 
the therapeutic value of using immunotherapies or immunomodulatory-based therapies for 
osteosarcoma [15, 62–64]. In this context, the number of new drugs activating the immune 
system has exploded in the last 10 years and numerous phase I and II clinical trials are in 
progress in osteosarcoma (Figure 1). In this chapter, the most recent therapeutic develop-
ments targeting the regulation of T lymphocytes and macrophages will be exposed.
2.3.1. T-cell therapies
Detection of specific T lymphocyte populations in the tumour microenvironment and in 
human tumour tissues defines an immunoscore and leads to patient stratification based on 
this immunophenotyping. These analyses have identified new predictive biomarkers and 
new therapeutic targets, which have stimulated the development of immunotherapies [65].
2.3.1.1. Disialoganglioside (GD2)
Monoclonal antibodies targeted against cell surface antigens specific to tumour cells have 
been proven to be effective in patients with breast cancer, lymphoma and neuroblastoma 
[66–68]. Usually these bispecific antibodies are engineered antibodies linking a tumour anti-
gen recognition domain to a second domain that activates a receptor on immune effector cells, 
typically T cells. The expression of the glycosphingolipid GD2 is restricted to the central and 
peripheral nervous system, skin (melanocyte) and mesenchymal cells located in the stroma 
[69–71]. In addition to the healthy tissues, GD2 was detected in neuroblastomas, melano-
mas, sarcomas, lung and central nervous system tumours, in which a variable number of 
cancer cells express this antigen [72–75]. Based on this relative restricted distribution, GD2-
targeting appeared very quickly as an interesting immunotherapy, especially for high-risk 
neuroblastomas, for which anti-GD2 antibodies improved significantly patient survival [68, 
76]. In patients with stage IV neuroblastoma, anti-GD2 antibody ch14.18 has been shown to 
improve EFS effectively when given in the setting of minimal residual disease. The rationale 
for using this antibody in patients with OS lies in that 95% of osteosarcoma express GD2 [77]. 
Consequently, given the success of anti-GD2 mAb therapy in neuroblastoma, studies explor-
ing the use of these mAbs in OS are underway [78]. Current trials include the GD2mAbs 
humanized3F8 (NCT01419834 and NCT01662804) and hu14.18K322A (NCT00743496) [61].
2.3.1.2. Nivolumab
Nivolumab is an immunomodulator, which acts by blocking the activation of the pro-
grammed cell death-1 (PD-1) receptor, induced by one of its two ligands (PD-L1) on activated 
T cells [79]. Numerous preclinical investigations have demonstrated that inhibition of the 
interaction between PD-1 and PD-L1 enhances the T-cell response, resulting in increased anti-
tumour activity. PD-L1 or PD-1 blockade with monoclonal antibodies results in strong and 
often rapid anti-tumour effects in several mouse models. A high PD-L1 expression has been 
identified in OS cell lines [80], and PD-1 expression on CD4 and CD8 T-cells was found higher 
in OS patients than in healthy controls and in patients with metastasis at diagnosis, high 
tumour stage or bone fracture [81]. A phase I/II trial will be conclude in 2016 on refractory 
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solid tumours and sarcomas including osteosarcoma. A total of 242 patients will be enrolled 
and treated with Nivolumab IV over 60 minutes twice a month. Courses repeat every 28 days 
in the absence of disease progression or unacceptable toxicity.
2.3.2. Immune and dendritic cell vaccine
Dendritic cells have the specific ability to initiate and modulate adaptive immune responses 
[82]. This specificity, associated with their role in antigen presentation, has led to their use in 
vaccine approaches in cancer. Matured autologous dendritic cells loaded with tumour lysates 
derived from tumour tissue were used as the vaccine product. In a pre-clinical model of osteo-
sarcoma, it has been demonstrated that killer dendritic cells were able to induce an adaptive 
anti-tumour immune response with a decrease in tumour development after cross-presentation 
of the tumour cell-derived antigen [83]. A phase I clinical trial demonstrated the feasibility and 
good tolerance of dendritic cells pulsed with MAGE-A1, MAGE-A3 and NYESO-1 full length 
peptides in combination with decitabine. Anti-tumour activity was observed in some patients 
[84]. In 2012, 12 osteosarcoma patients were vaccinated with tumour lysate pulsed dendritic 
cells, but evidence of a clinical benefit was observed in only two of these patients [85]. These 
authors concluded that osteosarcoma patients may be relatively insensitive to DC-based vac-
cine treatments. A new clinical trial was initiated, enrolling 56 patients (>1 year) with confirmed 
sarcoma, either relapsed or without known curative therapies, and treated with autologous den-
dritic cells pulsed with tumour lysate. NCT02409576 is a pilot trial (“Pilot Study of Expanded, 
Activated Haploidentical Natural Killer Cell Infusions for Sarcomas (NKEXPSARC)”) analys-
ing the effect of donor NK cells on clinical response determined by imaging. About 20 patients 
(aged 6 months–80 years) will be included between 2015 and 2016. The patients will receive lym-
phodepleting chemotherapy with cyclophosphamide (1 day) followed by fludarabine (5 days) 
and each patient will receive IL-2 1 day before infusion of the NK cell (total six doses).
2.3.3. Mifamurtide (liposomal-muramyl tripeptide phosphatidyl-ethanolamine L-MTP-PE)
As it has been discussed above, the density of TAM is linked to a poor diagnosis. In osteosar-
coma, Buddingh et al. showed that macrophages exhibit M1 and M2 phenotypes and demon-
strated a link between M2 macrophages and angiogenesis. Similarly, in preclinical models of 
osteosarcoma, the recruitment of the M2 subtype is correlated with tumour angiogenesis and 
lung metastasis [47, 50].
L-MTP-PE is a synthetic analogue of muramyl dipeptide of the bacterial cell walls, which 
was identified as a powerful activator or monocyte/macrophage lineage. Indeed, L-MTP-PE 
induces the expression of pro-inflammatory mediators such TNF-α, IL-1, IL-6, lympho-
cyte function-associated antigen 1 (LFA-1) and intercellular adhesion molecule 1 (ICAM1) 
leading to an M1 macrophage response. The therapeutic interest of L-MTP-PE was widely 
studied in osteosarcoma [86, 87]. The largest clinical experience with combination chemo-
therapy and L-MTP derives from the Intergroup 0133 osteosarcoma study. No difference 
in survival was found for patients who received ifosfamide in addition to the standard 
three-drug chemotherapy (doxorubicin, cisplatin and methotrexate). But this study did sug-
gest that L-MTP had a beneficial impact on survival, improving the 5-year overall survival 
rate from 70 to 78% (p = 0.03) [88]. However, no significant difference in survival was observed 
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between the two groups of treatment concerning the patients with metastatic disease (40% with-
out L-MTP versus 53% with L-MTP, p = 0.27). Based on these results, the European Medicines 
Agency granted L-MTP an indication for the treatment of non-metastatic osteosarcoma in 2009; 
the American Food and Drug Administration (FDA) did not. L-MTP is also approved for use 
in Turkey, Mexico and Israel. Recently, Biteau et al. have proved the efficacy of association 
of zoledronate and L-mifamurtide combination in osteosarcoma. This association induced an 
additional and in some cases synergistic inhibition of primary tumour progression [89].
2.3.4. Inhaled granulocyte-macrophage colony stimulating factor (GM-CSF)
GM-CSF is one of the master regulators of myeloid cell lineage by controlling their differen-
tiation, proliferation and activities. Indeed, this growth factor exerts immunomodulatory and 
immunostimulatory activities by stimulating the functional activities of neutrophil granulocytes 
but also of macrophages and DC. More specifically, GM-CSF promotes the recruitment and cyto-
toxic functions of macrophages, stimulates natural killer and dendritic cells, and consequently, 
upmodulates the number of CD4 T lymphocytes [90]. Arndt et al. have recently performed a 
phase I clinical trial using inhaled GM-CSF in patients with first isolated pulmonary recurrence 
of OS. Unfortunately, even though the clinical studies demonstrated the safety of administered 
GM-CSF (e.g. aerosolized delivery), no biological benefit (e.g. local immunomodulation in lung 
metastases) or improved clinical outcome was demonstrated. A future larger prospective ran-
domised trial may demonstrate improved outcomes in OS patients probably [91, 92].
3. Conclusion
The therapies focused on the immune niche partially represent the potential therapeutic tar-
gets available for OS nowadays. Blood vessels, bone cells and tumour cells are targeted as 
well in the current clinical trials. However, in the future, the key to success will lie in better 
understanding and characterisation of the disease, leading to better patient stratification and, 
consequently, to personalised medicine.
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